Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Mamoudou Maiga; Shichun Lun; Haidan Guo; Kathryn Winglee; Nicole C. Ammerman; William R. Bishai

doi:10.1093/infdis/jis269

Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Mamoudou Maiga, Shichun Lun, Haidan Guo, Kathryn Winglee, Nicole C. Ammerman, William R. Bishai

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

Original language	English (US)
Pages (from-to)	1705-1708
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	205
Issue number	11
DOIs	https://doi.org/10.1093/infdis/jis269
State	Published - Jun 1 2012

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/jis269

Cite this

@article{7febce096b0243068bc076f2df9fd87c,

title = "Risk of tuberculosis reactivation with tofacitinib (CP-690550)",

abstract = "Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.",

author = "Mamoudou Maiga and Shichun Lun and Haidan Guo and Kathryn Winglee and Ammerman, {Nicole C.} and Bishai, {William R.}",

note = "Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (grant numbers AI30036, AI37856 and AI36973) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Potential conflicts of interest. All authors: No reported conflicts.",

year = "2012",

month = jun,

day = "1",

doi = "10.1093/infdis/jis269",

language = "English (US)",

volume = "205",

pages = "1705--1708",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Risk of tuberculosis reactivation with tofacitinib (CP-690550)

AU - Maiga, Mamoudou

AU - Lun, Shichun

AU - Guo, Haidan

AU - Winglee, Kathryn

AU - Ammerman, Nicole C.

AU - Bishai, William R.

N1 - Funding Information: Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) (grant numbers AI30036, AI37856 and AI36973) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Potential conflicts of interest. All authors: No reported conflicts.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

AB - Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflammatory disorders, thus raising concerns of risk of active tuberculosis. Our goal was to characterize the impact of tofacitinib on LTBI using a mouse model of contained tuberculosis. Our data indicate that tofacitinib reduces host containment of Mycobacterium tuberculosis and promotes bacterial replication in the lungs, suggesting tuberculosis reactivation. Tofacitinib may carry a significant risk for LTBI reactivation in humans.

UR - http://www.scopus.com/inward/record.url?scp=84861043518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861043518&partnerID=8YFLogxK

U2 - 10.1093/infdis/jis269

DO - 10.1093/infdis/jis269

M3 - Article

C2 - 22474037

AN - SCOPUS:84861043518

SN - 0022-1899

VL - 205

SP - 1705

EP - 1708

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 11

ER -

Risk of tuberculosis reactivation with tofacitinib (CP-690550)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this